Dominique Carouge - Sanofi President

SNYNF Stock  USD 99.70  0.26  0.26%   

President

Mr. Dominique Carouge was appointed Executive Vice President Business Transformation, Member of the Executive Committee of the Company effective February 15, 2018. He has served as Deputy CFO and Head of Finance Operations and Group Controlling since January 1st, 2016. Mr. Carouge previously served as VicePresident, Administration Management for Global RD since 2011. Prior to that, Mr. Carouge held the role of VP, Chief Strategy and Finance Officer for Sanofi Pasteur since 2009. Mr. Carouge started his career in 1985 as an external auditor at Ernst Young both in France and in the US . He joined Sanofi in 1991. Since then and for the past 27 years, he held various finance positions of increasing responsibility and leadership across Australia, New Zealand, Germany and France. since 2018.
Tenure 6 years
Phone33 1 53 77 40 00
Webhttps://www.sanofi.com

Sanofi Management Efficiency

The company has return on total asset (ROA) of 0.0607 % which means that it generated a profit of $0.0607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0959 %, meaning that it generated $0.0959 on every $100 dollars invested by stockholders. Sanofi's management efficiency ratios could be used to measure how well Sanofi manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 14.86 B in total debt with debt to equity ratio (D/E) of 0.3, which may suggest the company is not taking enough advantage from borrowing. Sanofi has a current ratio of 1.27, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sanofi until it has trouble settling it off, either with new capital or with free cash flow. So, Sanofi's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sanofi sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sanofi to invest in growth at high rates of return. When we think about Sanofi's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Anne WhiteEli Lilly And
52
Peter FasoloJohnson Johnson
61
Ruud DobberAstraZeneca PLC ADR
N/A
Adam SchechterMerck Company
52
Paul HudsonAstraZeneca PLC ADR
N/A
Mark FishmanNovartis AG ADR
63
Patrick MDNovartis AG ADR
54
Barton PetersonEli Lilly And
57
Jasmina BrooksJohnson Johnson
N/A
MarieFrance TschudinNovartis AG ADR
53
Roger PerlmutterMerck Company
67
Michael HarringtonEli Lilly And
55
Kathy WengelJohnson Johnson
N/A
Christi ShawEli Lilly And
51
Mark MallonAstraZeneca PLC ADR
N/A
Susanne SchaffertNovartis AG ADR
54
Darren CarrollEli Lilly And
N/A
Adele AmbroseMerck Company
59
Willie DeeseMerck Company
59
Melissa BarnesEli Lilly And
52
Menelas PangalosAstraZeneca PLC ADR
57
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 95442 people. Sanofi [SNYNF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Sanofi Leadership Team

Elected by the shareholders, the Sanofi's board of directors comprises two types of representatives: Sanofi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi's management team and ensure that shareholders' interests are well served. Sanofi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
Emmanuel Babeau, Independent Director
Roy Papatheodorou, Gen VP
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee
Dieter Weinand, Executive Vice President Member of the Executive Board
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team
Eva SchaeferJansen, Head Relations
Fabienne Lecorvaisier, Director
George Grofik, Vice President of Investor Relations
Karen Linehan, Member of the Executive Board, Member of the Management Board, Senior Vice President General Counsel
Klaus Pohle, Independent Director
John Reed, President - Global Research & Development, Member of the Executive Committee
Bernard Charles, Independent Director
Melanie Lee, Independent Director
Pierre Chancel, Sr Marketing
Christophe Babule, Director
Bonnie Bassler, Director
Thomas Suedhof, Independent Director
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee
Laurent Attal, Director
JeanRene Fourtou, Independent Director
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee
Josephine Fubara, Chief Care
Christian Mulliez, Director
Robert Castaigne, Independent Director
Laurent Gilhodes, Principal Accounting
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team
Uwe Bicker, Independent Director
Josep Catlla, Head Communications
Claudie Haignere, Independent Director
Olivier Brandicourt, CEO, Director and Member of Strategy Committee
Paul Hudson, CEO Director
Bruno Mnard, Chief officer
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team
Dante Beccaria, Global VP
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team
Diane Souza, Independent Director
Carole Piwnica, Independent Director
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Igor Landau, Director
Patrick Kron, Independent Director
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee
Gerard Kemmel, Independent Director
SuetFern Lee, Independent Director
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee
Suet Lee, Independent Director

Sanofi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sanofi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Sanofi Pink Sheet analysis

When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Please note, there is a significant difference between Sanofi's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.